Literature DB >> 11934585

Synthesis and in vitro evaluation of a novel iodinated resiniferatoxin derivative that is an agonist at the human vanilloid VR1 receptor.

Mark E McDonnell1, Sui Po Zhang, Adrienne E Dubin, Scott L Dax.   

Abstract

Using a 'directed' iodination procedure, novel iodo-resiniferatoxin congeners were synthesized from 4-acetoxy-3-methoxyphenylacetic acid and resiniferinol- 9,13,14-ortho-phenylacetate (ROPA). The 2-iodo-4-hydroxy-5-methoxyphenylacetic acid ester of resiniferinol 5 displayed high affinity binding (K(i)=0.71 nM) for the human vanilloid VR1 receptor and functioned as a partial agonist.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11934585     DOI： 10.1016/s0960-894x(02)00127-0

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN： 0960-894X            Impact factor:   2.823


  10 in total

1.  Physiology and pharmacology of the vanilloid receptor.

Authors:  Angel Messeguer; Rosa Planells-Cases; Antonio Ferrer-Montiel
Journal:  Curr Neuropharmacol       Date:  2006-01       Impact factor: 7.363

2.  Receptor activity and conformational analysis of 5'-halogenated resiniferatoxin analogs as TRPV1 ligands.

Authors:  Kwang Su Lim; Dong Wook Kang; Yong Soo Kim; Myeong Seop Kim; Seul-Gi Park; Sun Choi; Larry V Pearce; Peter M Blumberg; Jeewoo Lee
Journal:  Bioorg Med Chem Lett       Date:  2010-11-05       Impact factor: 2.823

3.  Halogenation of 4-hydroxy/amino-3-methoxyphenyl acetamide TRPV1 agonists showed enhanced antagonism to capsaicin.

Authors:  Dong Wook Kang; Yong Soo Kim; Kwang Su Lim; Myeong Seop Kim; Larry V Pearce; Vladimir A Pavlyukovets; Andy K Tao; Krystle A Lang-Kuhs; Peter M Blumberg; Jeewoo Lee
Journal:  Bioorg Med Chem       Date:  2010-09-18       Impact factor: 3.641

4.  Lipopolysaccharide fever is initiated via a capsaicin-sensitive mechanism independent of the subtype-1 vanilloid receptor.

Authors:  M Devrim Dogan; Shreya Patel; Alla Y Rudaya; Alexandre A Steiner; Miklós Székely; Andrej A Romanovsky
Journal:  Br J Pharmacol       Date:  2004-10-18       Impact factor: 8.739

Review 5.  TRPV1 activation is not an all-or-none event: TRPV1 partial agonism/antagonism and its regulatory modulation.

Authors:  Peter M Blumberg; Larry V Pearce; Jeewoo Lee
Journal:  Curr Top Med Chem       Date:  2011       Impact factor: 3.295

6.  Neurogenic responses mediated by vanilloid receptor-1 (TRPV1) are blocked by the high affinity antagonist, iodo-resiniferatoxin.

Authors:  Michela Rigoni; Marcello Trevisani; David Gazzieri; Riccardo Nadaletto; Michele Tognetto; Christophe Creminon; John B Davis; Barbara Campi; Silvia Amadesi; Pierangelo Geppetti; Selena Harrison
Journal:  Br J Pharmacol       Date:  2003-03       Impact factor: 8.739

7.  Non-vanillyl resiniferatoxin analogues as potent and metabolically stable transient receptor potential vanilloid 1 agonists.

Authors:  Hyun-Kyung Choi; Sun Choi; Yoonji Lee; Dong Wook Kang; HyungChul Ryu; Han-Joo Maeng; Suk-Jae Chung; Vladimir A Pavlyukovets; Larry V Pearce; Attila Toth; Richard Tran; Yun Wang; Matthew A Morgan; Peter M Blumberg; Jeewoo Lee
Journal:  Bioorg Med Chem       Date:  2008-12-25       Impact factor: 3.641

8.  The carbonate analogues of 5'-halogenated resiniferatoxin as TRPV1 ligands.

Authors:  Kwang Su Lim; Hobin Lee; Sung Eun Kim; Tae-Hwan Ha; Jihyae Ann; Karam Son; Sun Choi; Wei Sun; Larry V Pearce; Ian A DeAndrea-Lazarus; Peter M Blumberg; Jeewoo Lee
Journal:  Eur J Med Chem       Date:  2013-08-09       Impact factor: 6.514

9.  Halogenation of a capsaicin analogue leads to novel vanilloid TRPV1 receptor antagonists.

Authors:  Giovanni Appendino; Selena Harrison; Luciano De Petrocellis; Nives Daddario; Federica Bianchi; Aniello Schiano Moriello; Marcello Trevisani; Francesca Benvenuti; Pierangelo Geppetti; Vincenzo Di Marzo
Journal:  Br J Pharmacol       Date:  2003-08       Impact factor: 8.739

10.  Novel scaffolds for modulation of TRPV1 identified with pharmacophore modeling and virtual screening.

Authors:  Daria Goldmann; Peter Pakfeifer; Steffen Hering; Gerhard F Ecker
Journal:  Future Med Chem       Date:  2015       Impact factor: 4.767
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.